AP Biosciences

AP Biosciences EBIT Margin

The EBIT Margin (Operating Margin) of AP Biosciences (6945.TWO) as of Nov 17, 2026 is -1,077.35 %. In the previous year, EBIT Margin (Operating Margin) was -2,670.06 % — a change of -59.65% (higher).

EBIT Margin

-1,077.35 %

YoY

-59.65%

Last updated:

EBIT Margin (Operating Margin) of AP Biosciences is 2023 -1,077.35 % . EBIT Margin (Operating Margin) of AP Biosciences was 2022 -2,670.06 % . It decreases by -59.65% higher compared to the previous year.

AP Biosciences's operating (EBIT) margin stands at -1,077.4%, down from 32.7% several years earlier.

The AP Biosciences EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2020
32.73 TWD
Jan 1, 2021
-2,670.06 TWD
Jan 1, 2023
-1,077.35 TWD
The AP Biosciences EBIT Margin history
YEAREBIT MarginYoY
-1,077.35 %-59.65%
-2,670.06 %-8,258.98%
32.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AP Biosciences Stock analysis

What does AP Biosciences do? AP Biosciences Inc generates revenue through the development and commercialization of protein and antibody drugs. The company focuses on early-stage drug candidates and preclinical trials, utilizing its technology platforms to create monoclonal and bispecific antibody drugs. Key products include IBI302, OmniMab, AP505, T-cube, and AP203, which target specific disease mechanisms and therapeutic areas. The primary buyers are pharmaceutical companies seeking to expand their drug pipelines through partnerships and licensing agreements. The firm's technology platforms, such as OmniMab fully human antibody library and T-cube, enable the development of novel bispecific antibodies. These platforms support the creation of drugs like AP505-PD-L1 x VEGF bispecific antibody and AP203-PD-L1 x CD137 fully human bispecific antibody, which are designed for specific therapeutic targets. The company's research and development efforts target diseases with high unmet medical needs, attracting interest from potential collaborators in the biopharmaceutical sector. AP Biosciences Inc's business model relies on advancing its pipeline of drug candidates through preclinical and clinical stages, with the goal of securing partnerships or licensing deals with larger pharmaceutical firms. The company's focus on bispecific antibody technology and its proprietary platforms positions it to generate revenue from milestone payments and royalties upon successful development and commercialization of its drug candidates. AP Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AP Biosciences stock

EBIT Margin (Operating Margin) of AP Biosciences is -1,077.35 % in 2023.

EBIT Margin (Operating Margin) of AP Biosciences changed from -2,670.06 % to -1,077.35 %, representing a -59.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) AP Biosciences since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s AP Biosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — AP Biosciences

All Key Metrics — AP Biosciences